Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 717.36 million. The enterprise value is 707.26 million.
| Market Cap | 717.36M |
| Enterprise Value | 707.26M |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | May 5, 2025 |
Share Statistics
Pharmanutra has 9.60 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | 9.60M |
| Shares Outstanding | 9.60M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -1.60% |
| Owned by Insiders (%) | 65.62% |
| Owned by Institutions (%) | 13.06% |
| Float | 3.30M |
Valuation Ratios
The trailing PE ratio is 35.74 and the forward PE ratio is 29.40.
| PE Ratio | 35.74 |
| Forward PE | 29.40 |
| PS Ratio | 5.35 |
| PB Ratio | 10.07 |
| P/TBV Ratio | 15.34 |
| P/FCF Ratio | 43.66 |
| P/OCF Ratio | 36.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.67, with an EV/FCF ratio of 43.05.
| EV / Earnings | 35.36 |
| EV / Sales | 5.28 |
| EV / EBITDA | 20.67 |
| EV / EBIT | 23.33 |
| EV / FCF | 43.05 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.35 |
| Quick Ratio | 1.81 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 0.60 |
| Debt / FCF | 1.25 |
| Interest Coverage | 27.86 |
Financial Efficiency
Return on equity (ROE) is 29.85% and return on invested capital (ROIC) is 31.69%.
| Return on Equity (ROE) | 29.85% |
| Return on Assets (ROA) | 15.61% |
| Return on Invested Capital (ROIC) | 31.69% |
| Return on Capital Employed (ROCE) | 32.18% |
| Weighted Average Cost of Capital (WACC) | 5.81% |
| Revenue Per Employee | 985,059 |
| Profits Per Employee | 147,074 |
| Employee Count | 136 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 11.25 |
Taxes
In the past 12 months, Pharmanutra has paid 10.27 million in taxes.
| Income Tax | 10.27M |
| Effective Tax Rate | 34.03% |
Stock Price Statistics
The stock price has increased by +52.92% in the last 52 weeks. The beta is 0.30, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +52.92% |
| 50-Day Moving Average | 66.72 |
| 200-Day Moving Average | 53.11 |
| Relative Strength Index (RSI) | 66.32 |
| Average Volume (20 Days) | 33,673 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 133.97 million and earned 20.00 million in profits. Earnings per share was 2.09.
| Revenue | 133.97M |
| Gross Profit | 45.16M |
| Operating Income | 30.31M |
| Pretax Income | 30.19M |
| Net Income | 20.00M |
| EBITDA | 34.21M |
| EBIT | 30.31M |
| Earnings Per Share (EPS) | 2.09 |
Balance Sheet
The company has 30.62 million in cash and 20.51 million in debt, with a net cash position of 10.10 million or 1.05 per share.
| Cash & Cash Equivalents | 30.62M |
| Total Debt | 20.51M |
| Net Cash | 10.10M |
| Net Cash Per Share | 1.05 |
| Equity (Book Value) | 71.24M |
| Book Value Per Share | 7.50 |
| Working Capital | 41.87M |
Cash Flow
In the last 12 months, operating cash flow was 19.56 million and capital expenditures -3.13 million, giving a free cash flow of 16.43 million.
| Operating Cash Flow | 19.56M |
| Capital Expenditures | -3.13M |
| Depreciation & Amortization | 3.90M |
| Net Borrowing | -3.76M |
| Free Cash Flow | 16.43M |
| FCF Per Share | 1.71 |
Margins
Gross margin is 33.71%, with operating and profit margins of 22.63% and 14.93%.
| Gross Margin | 33.71% |
| Operating Margin | 22.63% |
| Pretax Margin | 22.53% |
| Profit Margin | 14.93% |
| EBITDA Margin | 25.54% |
| EBIT Margin | 22.63% |
| FCF Margin | 12.26% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.58%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.58% |
| Dividend Growth (YoY) | 17.65% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 47.95% |
| Buyback Yield | 0.40% |
| Shareholder Yield | 1.99% |
| Earnings Yield | 2.79% |
| FCF Yield | 2.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmanutra has an Altman Z-Score of 7.8 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.8 |
| Piotroski F-Score | 5 |